晨光生物(300138.SZ):一季度淨利潤預增133.21%至210.95%
格隆匯4月7日丨晨光生物(300138.SZ)公佈2025年第一季度業績預告,1-3月公司實現歸屬於上市公司股東的淨利潤盈利9,000萬元—12,000萬元,比上年同期上升133.21%至210.95%;歸屬於上市公司股東扣除非經常性損益後的淨利潤盈利7,500萬元—10,500萬元,比上年同期上升54.68%至116.55%。
報告期,公司植提類業務持續發力,是公司業績的“基石”;棉籽類相關產品隨豆油、豆粕等大宗商品行情逐漸回暖,棉籽類業務較上年同期實現扭虧爲盈;公司整體業績同比上升。
經初步測算,公司預計實現歸屬於上市公司股東的淨利潤9,000萬元至12,000萬元,同比上升133.21%至210.95%,其中非經常性損益影響金額約爲1,500萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.